According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...

The US FDA has granted approval for AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for ...

The FDA has approved at-home self- or caregiver-administration of FluMist (influenza vaccine live, intranasal).

AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for self-administration. The approval makes FluMist the only 'flu vaccine ...

FluMist has been sold at pharmacies for years, but now it will be available to use at home as early as next year.

FluMist, a needle-free nasal spray influenza vaccine, has been approved by the FDA for self-administration in the US, making ...

The EMA CHMP has recommended granting approval for AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis ...

AstraZeneca says FluMist has been shown to be as effective as other flu vaccines.When the FDA announced last year that it was reviewing the possibility of a self-administered flu vaccine, physicians ...

FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States since 2003.

AstraZeneca’s share price has fallen following unfavourable results for one of its new drugs, but others look good, and ...